Le 21 mars 2017, la Cour fédérale a rejeté la demande d’ordonnance d’interdiction présentée par les demanderesses en vertu du Règlement sur les médicaments brevetés (avis de conformité) relativement au produit générique dasatinib proposé par Apotex. La Cour a conclu au bien-fondé des allégations d’invalidité présentées par Apotex relativement aux brevets canadiens numéros 2366932 et 2519898.

Nia Wine Group Co., Ltd. v. North 42 Degrees Estate Winery Inc., 2022 FC 241

Frac Shack Inc. c. AFD Petroleum Ltd, 2018 CF 1047

Hutchingame Growth Capital Corporation v. Dayton Boot Co. Enterprises Ltd, 2019 FCA 152

TatuYou filed a statement of claim alleging that H2Ocean, Inc. infringed a patent for a “transparent breathable polyurethane film for tattoo aftercare and method.

In this decision, the Federal Court of Appeal dismissed Live! Holdings, LLC’s appeal of a Federal Court decision that upheld a decision of the Registrar of Trademarks to expunge Live!’s Canadian trademark registration no. TMA 789, 912 from the Register of Trademarks.

Hospira Healthcare Corporation and the other appellants (“Hospira”) appealed to the Federal Court of Appeal from two decisions of a Federal Court judge. Both decisions refused to allow Hospira to amend its Statement of Issues in the underlying bifurcated patent infringement and validity action. The first motion was dismissed by a prothonotary and then by the Federal Court judge on appeal, and the second motion attempted to assert the same claim in greater detail.